CYTH News and Press, Cyclo Therapeutics Inc. From 04/09/21

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Insiders are people who have access to private information about a company and can do something called insider buying . They include a company’s senior management, members of the board of directors and other importa...

Gainers: ProQR Therapeutics (PRQR) +47%.Cellect Biotechnology (APOP) +47%.Houston Wire & Cable (HWCC) +38%.GameStop (GME) +29%.Koss (KOSS) +28%.Cinedigm (CIDM) +28%.F-star Therapeutics (FSTX) +26%.FreightCar America (RAIL) +24%.Polar Power (POLA) +20%.Immutep (IMMP) +20%.Losers:...

Cyclo Therapeutics (CYTH) announces positive topline data from its Phase 1/2 clinical trial, which showed promising safety and efficacy results for Trappsol Cyclo in the treatment of Niemann-Pick Disease type C1, a rare genetic disease causing cholesterol accumulation in cells,...

(CYTH): FY GAAP EPS of -$5.60 misses by $3.85.Revenue of $0.9M (-10.9% Y/Y) misses by $0.31M.Shares +7.08% PM.10KPress Release For further details see: EPS misses by $3.85, misses on revenue

- Multiple value-driving milestones expected throughout 2021 - Trappsol ® Cyclo™ Niemann Pick Disease Type C (NPC) clinical program on track to imminently report topline results from Phase 1/2 study - Company expects to commence enrollment in pivotal Ph...

Cyclo Therapeutics (CYTH) appoints Russ Belden as acting Chief Commercial Officer.Mr. Belden is a commercialization leader with over 33 years of senior leadership experience in the biotechnology industry, specializing in strategic marketing, sales management, sales training, an...

Preeminent biotechnology commercialization leader with over 33 years of industry experience, including 16 years at Genentech with a pivotal role in commercializing products across multiple therapeutic areas Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeut...

Cyclo Therapeutics (CYTH) gets positive opinion from the Paediatric Committee ((PDCO)) of the European Medicines Agency ((EMA)) on its agreement with the proposed Paediatric Investigation Plan ((PIP)) for Trappsol Cyclo, currently in development for the treatment of Niemann-Pic...

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease, today ...

Cyclo Therapeutics (CYTH) announces that the last patient completed their last visit in the Phase 1/2 study evaluating Trappsol Cyclo, a proprietary formulation of hydroxypropyl beta cyclodextrin, administered intravenously to patients with Niemann-Pick Disease Type C1 ((NPC1)), ...